DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Denali Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.04+0.43 (+2.44%)
Close on Oct 19, 2026
- Market cap
- $3.38B
- P/E (TTM)
- –
- Dividend yield
- –
Denali Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.88B | $166.30M |
| Enterprise Value | $2.17B | $88.19M |
| PB Ratio | 3.45 | 2.03 |
| P/TBV Ratio | 3.60 | 2.29 |
Income (trailing twelve months)
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$542.70M | -$21.40M |
| Net Income | -$511.45M | -$22.46M |
| EBITDA | -$530.47M | -$16.91M |
| EPS (Diluted) | -$2.84 | -$0.83 |
Returns
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -54.9% | -53.2% |
| Return on Assets (ROA) | -44.0% | -40.9% |
| Return on Invested Capital (ROIC) | -343.4% | -32.4% |
| Return on Capital Employed (ROCE) | -50.8% | -38.1% |
Balance sheet
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $710.47M | $61.43M |
| Net Cash (Debt) | $710.47M | $15.35M |
| Net Cash Per Share | $4.44 | $0.66 |
| Equity (Book Value) | $835.18M | $49.09M |
| Book Value Per Share | $5.22 | $1.37 |
| Tangible Book Value | $799.93M | $23.52M |
| Working Capital | $663.84M | $76.81M |
Financial position
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.37 | 3.34 |
| Quick Ratio | 7.93 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$434.04M | -$12.35M |
| Capital Expenditures | -$3.42M | -$1.08M |
| Free Cash Flow | -$437.46M | -$20.22M |
| FCF Per Share | -$2.74 | -$0.42 |
Efficiency
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.02M | -$703.34K |
| Employee Count | 503 | 74 |
Dividends and yields
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -17.7% | -23.3% |
| FCF Yield | -15.2% | -8.72% |
Shares
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 159,847,000 | 58,127,000 |
| Shares Change (YoY) | 5.81% | 10.9% |
| Shares Change (QoQ) | 0.69% | 0.54% |
| Float | 149,229,000 | 49,136,700 |
| Shares Held by Insiders | 6.64% | 11.6% |
| Shares Held by Institutions | 97.7% | 59.4% |
Scores
| Measure | Denali Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.71 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Denali Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.